Laurence Hatteville

829 total citations
10 papers, 384 citations indexed

About

Laurence Hatteville is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Laurence Hatteville has authored 10 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 3 papers in Cancer Research. Recurrent topics in Laurence Hatteville's work include HER2/EGFR in Cancer Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (2 papers). Laurence Hatteville is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (2 papers). Laurence Hatteville collaborates with scholars based in France, United States and Italy. Laurence Hatteville's co-authors include Petr Karásek, Robert Manges, Hanno Riess, Sylvie Assadourian, Philippe Rougier, Yves Humblet, C. Barone, Armando Santoro, Philip A. Philip and Franck Morschhauser and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Laurence Hatteville

10 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laurence Hatteville France 8 295 101 92 74 70 10 384
H. S. Hochster United States 12 430 1.5× 112 1.1× 36 0.4× 45 0.6× 79 1.1× 21 517
S. Loibl Germany 10 254 0.9× 49 0.5× 62 0.7× 96 1.3× 93 1.3× 30 516
Raquel Bratos Spain 8 327 1.1× 92 0.9× 53 0.6× 83 1.1× 116 1.7× 13 609
Hong Cen China 8 128 0.4× 119 1.2× 58 0.6× 45 0.6× 91 1.3× 16 348
Nicole Kelbick United States 7 260 0.9× 95 0.9× 79 0.9× 101 1.4× 158 2.3× 9 522
Naseer Qayum United Kingdom 11 247 0.8× 174 1.7× 87 0.9× 68 0.9× 89 1.3× 21 358
Eric Cheung United States 11 244 0.8× 228 2.3× 79 0.9× 24 0.3× 96 1.4× 21 498
M Andreeff United States 8 135 0.5× 137 1.4× 64 0.7× 34 0.5× 90 1.3× 14 373
Ingirídur Skírnisdóttir Sweden 16 234 0.8× 87 0.9× 55 0.6× 107 1.4× 176 2.5× 26 682
David Pérez-Callejo Spain 11 201 0.7× 115 1.1× 39 0.4× 111 1.5× 59 0.8× 23 328

Countries citing papers authored by Laurence Hatteville

Since Specialization
Citations

This map shows the geographic impact of Laurence Hatteville's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Hatteville with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Hatteville more than expected).

Fields of papers citing papers by Laurence Hatteville

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Hatteville. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Hatteville. The network helps show where Laurence Hatteville may publish in the future.

Co-authorship network of co-authors of Laurence Hatteville

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Hatteville. A scholar is included among the top collaborators of Laurence Hatteville based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Hatteville. Laurence Hatteville is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Coiffier, Bertrand, Catherine Thiéblemont, Sophie de Guibert, et al.. (2016). A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma. British Journal of Haematology. 173(5). 722–730. 46 indexed citations
2.
Stjepanovic, Neda, Min‐Hee Ryu, Josep Tabernero, et al.. (2016). First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848). European Journal of Cancer. 69. S14–S15. 8 indexed citations
3.
Kantarjian, Hagop M., Bruno Lioure, Stella K. Kim, et al.. (2015). A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 16(3). 139–145. 52 indexed citations
4.
Trněný, Marek, Gregor Verhoef, Martin J.S. Dyer, et al.. (2014). Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. Journal of Clinical Oncology. 32(15_suppl). 8506–8506. 12 indexed citations
5.
6.
Rougier, Philippe, Hanno Riess, Robert Manges, et al.. (2013). Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European Journal of Cancer. 49(12). 2633–2642. 145 indexed citations
7.
8.
9.
Hatteville, Laurence, Cédric Mahé, & Catherine Hill. (2002). Prediction of the long‐term survival in breast cancer patients according to the present oncological status. Statistics in Medicine. 21(16). 2345–2354. 15 indexed citations
10.
Tramalloni, Dominique, et al.. (2000). Contrôle ultime pré-transfusionnel: évaluation de sept dispositifs. Transfusion Clinique et Biologique. 7(2). 129–139. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. S. Hochster Breakdown of academic impact, for papers by S. Loibl Breakdown of academic impact, for papers by Raquel Bratos Breakdown of academic impact, for papers by Hong Cen Breakdown of academic impact, for papers by Nicole Kelbick Breakdown of academic impact, for papers by Naseer Qayum Breakdown of academic impact, for papers by Eric Cheung Breakdown of academic impact, for papers by M Andreeff Breakdown of academic impact, for papers by Ingirídur Skírnisdóttir Breakdown of academic impact, for papers by David Pérez-Callejo
Rankless by CCL
2026